EDSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edesa Biotech Inc (EDSA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown a significant price decline (-5.98% in the regular market and -3.18% post-market), no positive trading trends, no recent news catalysts, and weak financial performance. Additionally, there are no proprietary trading signals indicating a buy opportunity. The technical indicators are mixed, with bullish moving averages but a neutral RSI and MACD. Considering the lack of positive catalysts and the company's poor financial performance, this stock does not align with the user's investment goals.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the RSI is neutral at 65.495, and the MACD histogram is positively contracting at 0.212. Key support is at 4.333, and resistance is at 8.298. The stock has a 50% chance to decline -2.45% in the next week and only a 0.68% chance to increase in the next month.
NULL identified. No recent news or significant trading trends.
and declining EPS (-41.67% YoY).
In Q1 2026, revenue remained at $0 with no growth. Net income improved by 38.98% YoY but remains negative at -$2,247,669. EPS dropped by -41.67% YoY to -0.28, and gross margin remained at 0.
No analyst rating or price target changes available.
